Inhaled cannabis has been shown to reduce chronic pain, however its intoxicating effects present a clinical limitation. Several studies support the popular notion that CBD (cannabidiol) can reduce THC (trans-Δ⁹-tetrahydrocannabinol) subjective effects, yet multiple other studies demonstrate that CBD can actually enhance THC's intoxicating effects. These discrepancies are dependent upon the two cannabinoids’ ratios and concentrations. We hypothesize that the majority of medical cannabis products with THC and CBD will have ratios capable of producing significant acute intoxication, similar to recreational products. This study subsequently aims to characterize cannabis products available from dispensaries within ratio and concentration categories, and evaluate whether the probable effects of products labeled as recreational differ from those labeled as medical to determine their potential utility for chronic pain. We collected THC and CBD content from cannabis products offered by 653 dispensaries online from nine states (CA, CO, ME, MA, NH, NM, RI, VT, WA). A total of 8,505 herbal cannabis products were recorded, with 6,293 offering information on CBD content. The 72.8% of products containing CBD (>0%) fall into four clinically meaningful categories: CBD can enhance THC effects (THC:CBD ratios ≥ 1:1), CBD has no significant effect on THC effects (ratios ∼1:2), CBD can either have no effect or is protective against THC effects (ratios 1: >2